Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of an experimental model for liver abscess induction in Holstein steers using an acidotic diet challenge and bacterial inoculation.
McDaniel ZS, Hales KE, Salih H, Deters A, Shi X, Nagaraja TG, Lawrence TE, Tennant TC, Amachawadi RG, Carroll JA, Burdick Sanchez NC, Galyean ML, Smock TM, Ballou MA, Machado VS, Davis E, Broadway PR. McDaniel ZS, et al. Among authors: salih h. J Anim Sci. 2024 Jan 3;102:skae046. doi: 10.1093/jas/skae046. J Anim Sci. 2024. PMID: 38447078
Assessment of pain associated with bovine respiratory disease and its mitigation with flunixin meglumine in cattle with induced bacterial pneumonia.
Martin MS, Kleinhenz MD, White BJ, Johnson BT, Montgomery SR, Curtis AK, Weeder MM, Blasi DA, Almes KM, Amachawadi RG, Salih HM, Miesner MD, Baysinger AK, Nickell JS, Coetzee JF. Martin MS, et al. J Anim Sci. 2022 Feb 1;100(2):skab373. doi: 10.1093/jas/skab373. J Anim Sci. 2022. PMID: 34932121 Free PMC article.
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C, Özbek M, Martus P, Hackenbruch C, Englisch A, Heitmann JS, Salih HR, Walz JS. Jung S, et al. Among authors: salih hr. Front Oncol. 2024 Oct 14;14:1458449. doi: 10.3389/fonc.2024.1458449. eCollection 2024. Front Oncol. 2024. PMID: 39469638 Free PMC article.
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Among authors: salih hr. Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14304. Online ahead of print. Eur J Haematol. 2024. PMID: 39400388
Targeting CD276 for T cell-based immunotherapy of breast cancer.
Hagelstein I, Wessling L, Rochwarger A, Zekri L, Klimovich B, Tegeler CM, Jung G, Schürch CM, Salih HR, Lutz MS. Hagelstein I, et al. Among authors: salih hr. J Transl Med. 2024 Oct 4;22(1):902. doi: 10.1186/s12967-024-05689-4. J Transl Med. 2024. PMID: 39367484 Free PMC article.
Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider IJ, Corbacioglu A, Gaidzik VI, Meid A Dr, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf GG, Salwender HJ, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol FR, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Among authors: salih hr. Blood Adv. 2024 Sep 30:bloodadvances.2024013758. doi: 10.1182/bloodadvances.2024013758. Online ahead of print. Blood Adv. 2024. PMID: 39348668
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.
Englisch A, Hayn C, Jung S, Heitmann JS, Hackenbruch C, Maringer Y, Nelde A, Wacker M, Denk M, Zieschang L, Kammer C, Martus P, Salih HR, Walz JS. Englisch A, et al. Among authors: salih hr. Front Oncol. 2024 Aug 26;14:1441625. doi: 10.3389/fonc.2024.1441625. eCollection 2024. Front Oncol. 2024. PMID: 39252947 Free PMC article.
356 results